Impact of Immune Reconstitution-Induced Hepatic Flare on Hepatitis B Surface Antigen Loss in Hepatitis B Virus/Human Immunodeficiency Virus-1 Coinfected Patients

Hepatitis B surface antigen (HBsAg) loss is an ideal goal for chronic hepatitis B patients. Antiretroviral therapy (ART) in hepatitis B virus/human immunodeficiency virus-1 (HBV/HIV-1)–coinfected patients can lead to hepatic flare (HF) caused by immune reconstitution-induced inflammatory syndrome (IRIS). Here, we investigated the impact of IRIS-HF on HBsAg loss. This was a retrospective study of 58 HBV/HIV-1–coinfected subjects HBsAg-positive for ≥6 months before ART initiation and followed for ≥1 year (median 9.9 years) after ART initiation. We examined humoral factors in sera from healthy volunteers, HIV-monoinfected patients, and HBV/HIV-1–coinfected patients with IRIS-HF or acute hepatitis B infection. During ART, HBsAg loss was observed in 20 of 58 HBV/HIV-1–coinfected patients (34.5%). Of the 58 patients, 15 (25.9%) developed IRIS-HF within 12 months of ART initiation. HBsAg loss was more frequent among patients who developed IRIS-HF (11/15, 73.3%) than those who did not (9/43, 20.9%). Multivariate analysis showed IRIS-HF was an independent predictor of subsequent HBsAg loss. Younger age and higher baseline HBV DNA titer were associated with IRIS-HF. Elevation of sCD163, not CXCL9, CXC10, CXCXL11, or CXCL13, was observed at IRIS-HF. IRIS-HF was associated with HBsAg loss in HBV/HIV-1–coinfected patients.

[1]  Hengning Ke,et al.  Long‐term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co‐infected Chinese , 2020, Journal of viral hepatitis.

[2]  R. Chung,et al.  High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia. , 2019, The Journal of infectious diseases.

[3]  L. Galli,et al.  OUTCOME OF ACUTE HEPATITIS B VIRUS INFECTION IN HIV-1 INFECTED PATIENTS: POSSIBLE FACTORS ASSOCIATED WITH RESOLUTION OR CHRONICITY , 2019, Journal of acquired immune deficiency syndromes.

[4]  Hsin-Yun Sun,et al.  Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection , 2019, Hepatology International.

[5]  P. Delobel,et al.  Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection , 2019, PloS one.

[6]  A. Seetharam,et al.  Immune Reconstitution Syndrome with Initiation of Treatment of HBV/HIV Co-infection: Activity Flare associated with E antigen Seroconversion. , 2019, Annals of hepatology.

[7]  C. Delaugerre,et al.  Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co‐infected patients from Western Africa , 2018, Journal of viral hepatitis.

[8]  P. Marcellin,et al.  ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg‐positive chronic hepatitis B , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[9]  S. Guha,et al.  Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy , 2018, Indian journal of medical microbiology.

[10]  S. Lewin,et al.  HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment , 2017, AIDS.

[11]  Xing Liu,et al.  More improvement than progression of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV‐infected patients with or without HBV and HCV co‐infections , 2017, Journal of viral hepatitis.

[12]  E. Engels,et al.  Evolving epidemiology of HIV-associated malignancies , 2017, Current opinion in HIV and AIDS.

[13]  A. Mocroft,et al.  Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons , 2016, AIDS.

[14]  F. Sarfo,et al.  Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  A. Phillips,et al.  Factors Associated With Plasma IL-6 Levels During HIV Infection. , 2015, The Journal of infectious diseases.

[16]  V. Soriano,et al.  Emerging Challenges in Managing Hepatitis B in HIV Patients , 2015, Current HIV/AIDS Reports.

[17]  Y. Liaw,et al.  Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. , 2014, Journal of hepatology.

[18]  O. Kirk,et al.  Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration , 2014, The Lancet.

[19]  B. Clotet,et al.  Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study , 2014, The Lancet.

[20]  H. Lee,et al.  HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability , 2013, Gut.

[21]  P. Rosenthal,et al.  Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. , 2013, The Journal of clinical investigation.

[22]  S. Lewin,et al.  Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. , 2013, The Journal of infectious diseases.

[23]  S. Lewin,et al.  Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Yoshiyuki Suzuki,et al.  Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study , 2013, Journal of Gastroenterology.

[25]  A. Rieger,et al.  Five‐year on‐treatment efficacy of lamivudine‐, tenofovir‐ and tenofovir + emtricitabine‐based HAART in HBV–HIV‐coinfected patients , 2012, Journal of viral hepatitis.

[26]  S. Lewin,et al.  Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand , 2012, AIDS Research and Therapy.

[27]  Helen M. Chun,et al.  Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. , 2012, The Journal of infectious diseases.

[28]  A. Mocroft,et al.  Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption , 2010, AIDS.

[29]  S. Lewin,et al.  Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. , 2009, The Journal of infectious diseases.

[30]  E. Nicolas,et al.  Assembly of Hepatitis Delta Virus: Particle Characterization, Including the Ability To Infect Primary Human Hepatocytes , 2007, Journal of Virology.

[31]  S. Nair,et al.  Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? , 2001, Hepatology.

[32]  F. Zavala,et al.  Inflammatory cytokines and inhibitors in HIV infection: correlation between interleukin-1 receptor antagonist and weight loss , 1996, AIDS.